Abbott beats Q2 consensus; Diagnostics revenues increased by 4.7% to $1.99B

Abbott Laboratories (ABT) Q2 results:

Revenues: $7,328M (-8.2%); Nutrition: $1,883M (+0.4%); Diagnostics: $1,994M (+4.7%); Established Pharmaceuticals: $1,013M; Medical Devices: $2,423M (-21.2%).

Net Income: $537M (-46.6%); EPS: $0.30 (-46.4%); non-GAAP Net Income: $1,018M (-30.5%); non-GAAP EPS: $0.57 (-30.5%).

2020 Guidance: EPS: at least $2.00; non-GAAP EPS: at least $3.25. The average analyst estimate for non-GAAP EPS is $2.86.

Shares are up 1% premarket.

Previously: Abbott Laboratories EPS beats by $0.15, beats on revenue (July 16)

https://seekingalpha.com/news/3591787-abbott-beats-q2-consensus-diagnostics-revenues-increased-4_7-to-1_99b